This antibody-drug the conjugate represents a important breakthrough in the treatment of aggressive myeloid malignancy, mainly aggressive myeloid disease (AML). The antibody-drug joins a monoclonal immunoglobulin https://dirstop.com/story28291104/this-antibody-drug-ozogamicin-a-full-examination